Michael Freeman

Stock Analyst at Raymond James

(2.86)
# 1,830
Out of 5,043 analysts
6
Total ratings
80%
Success rate
20.32%
Average return

Stocks Rated by Michael Freeman

Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $7.62
Upside: +83.73%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $18.62
Upside: +308.16%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $24.17
Upside: +53.08%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $89.65
Upside: -0.73%
Avidity Biosciences
Jun 11, 2025
Initiates: Strong Buy
Price Target: $65
Current: $70.00
Upside: -7.14%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $6.20
Upside: +29.03%